Specialty pharmacy tech provider Free Market Health snagged a $20 million Series B round, CEO Joe Cardosi tells Axios exclusively.
Why it matters: Specialty drugs must pass through multiple layers of approval and verification before reaching the patient, resulting in delays that irk patients and may be linked with poorer health outcomes.
